Manish A. Shah, MD, discusses the potential clinical implications of the ongoing phase 3 GLOW trial in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction adenocarcinoma.
Manish A. Shah, MD, Bartlett Family Professor in Gastrointestinal Oncology, professor of medicine, Weill Cornell Medical College, Cornell University, attending physician, NewYork-Presbyterian Hospital, discusses the potential clinical implications of the ongoing phase 3 GLOW trial (NCT03653507) in Claudin 18.2-positive, HER2-negative gastric/gastroesophageal junction (GEJ) adenocarcinoma.
The GLOW trial was designed to evaluate frontline zolbetuximab plus CAPOX vs placebo plus CAPOX in patients with Claudin 18.2-positive, HER2-negative gastric/GEJ adenocarcinoma. Patients are considered Claudin 18.2-positive if at least 75% of tumor cells demonstrate moderate to strong immunohistochemistry staining. Notably, about 30% to 35% of patients with gastric/GEJ adenocarcinoma are thought to meet this criterion and would therefore be eligible for the regimen should it move forward in clinical development, Shah explains. The results of the GLOW trial could be practice changing if they are positive because they will establish another actionable target in the gastric/GEJ cancer paradigm, Shah adds.
Although advances with immunotherapy and targeted therapy have been made in gastric/GEJ cancers, most patients are not cured of their disease, so novel treatment options are needed, Shah concludes.